CSS
ATXI

Cubist Systematic Strategies’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Cubist Systematic Strategies’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-145
Closed -$1.76K – 4376
2023
Q4 		$1.76K Buy
+145
New +$3.39K ﹤0.01% 3457

Other funds holding ATXI

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Cubist Systematic Strategies's ATXI Position: Q1 2024 in Review

Cubist Systematic Strategies sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2024, closing a stake of 145 shares — an estimated $1.76K sold.

Cubist Systematic Strategies first reported a position in ATXI in Q4 2023 and held it in 1 quarter. The position peaked at $1.76K in Q4 2023. 13 funds tracked by Wall St. Rank hold ATXI as of Q1 2024.

  • Cubist Systematic Strategies reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Cubist Systematic Strategies sold 145 Avenue Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $1.76K.
  • Cubist Systematic Strategies first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • Cubist Systematic Strategies's Avenue Therapeutics, Inc. Common Stock position peaked at $1.76K in Q4 2023.
  • 13 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Cubist Systematic Strategies's 13F filing for Q1 2024, filed 15 May 2024.